HC Wainwright Issues Optimistic Forecast for UNCY Earnings

Key Points

• HC Wainwright raised its Q3 2026 EPS estimate for Unicycive Therapeutics to a loss of $0.39 per share from $0.40, while maintaining a “Buy” rating and $13 price target.
• Analyst sentiment remains broadly positive, with five Buy ratings, one Hold, and one Sell; the consensus price target is $18.25. Shares recently traded near $4.70, despite remaining unprofitable.
• Unicycive resubmitted its NDA for oxylanthanum carbonate with additional manufacturing data addressing FDA concerns, creating a potential regulatory catalyst. However, FDA acceptance and approval are not guaranteed, and related securities litigation adds legal and regulatory risk.

Unicycive Therapeutics, Inc. (NASDAQ:UNCY - Free Report) - Stock analysts at HC Wainwright boosted their Q3 2026 earnings per share (EPS) estimates for Unicycive Therapeutics in a research note issued to investors on Tuesday, September 29th. HC Wainwright analyst S. Ramakanth now anticipates that the company will post earnings per share of ($0.39) for the quarter, up from their prior estimate of ($0.40). HC Wainwright has a "Buy" rating and a $13.00 price target on the stock. The consensus estimate for Unicycive Therapeutics' current full-year earnings is ($1.17) per share. HC Wainwright also issued estimates for Unicycive Therapeutics' Q4 2026 earnings at ($0.39) EPS, FY2026 earnings at ($1.38) EPS, Q1 2027 earnings at ($0.43) EPS, Q2 2027 earnings at ($0.28) EPS, Q3 2027 earnings at ($0.19) EPS, Q4 2027 earnings at $0.04 EPS, FY2027 earnings at ($0.86) EPS, FY2028 earnings at $2.85 EPS, FY2029 earnings at $3.75 EPS and FY2030 earnings at $4.98 EPS.

Several other research analysts also recently weighed in on UNCY. Benchmark reiterated a "speculative buy" rating and set a $15.00 price target (up from $13.00) on shares of Unicycive Therapeutics in a research note on Thursday, August 20th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Unicycive Therapeutics in a report on Friday, September 4th. Zacks Research raised shares of Unicycive Therapeutics from a "strong sell" rating to a "hold" rating in a research note on Wednesday, August 19th. B. Riley Financial reiterated a "buy" rating and issued a $20.00 price objective (down from $22.00) on shares of Unicycive Therapeutics in a report on Wednesday, August 12th. Finally, Guggenheim reaffirmed a "buy" rating and issued a $25.00 price objective (down from $37.00) on shares of Unicycive Therapeutics in a research note on Thursday, August 13th. Five equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $18.25.

Unicycive Therapeutics Stock Up 3.3%

Unicycive Therapeutics stock opened at $4.70 on Thursday. The firm has a 50 day moving average price of $5.13 and a 200-day moving average price of $6.29. Unicycive Therapeutics has a twelve month low of $3.93 and a twelve month high of $8.74. The company has a market capitalization of $130.90 million, a P/E ratio of -2.69 and a beta of 1.79.

Unicycive Therapeutics (NASDAQ:UNCY - Get Free Report) last announced its earnings results on Wednesday, August 12th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.47) by $0.41.

Institutional Trading of Unicycive Therapeutics

Large investors have recently bought and sold shares of the company. Dimensional Fund Advisors LP purchased a new stake in Unicycive Therapeutics in the first quarter worth about $940,000. Seven Fleet Capital Management LP bought a new position in shares of Unicycive Therapeutics during the first quarter valued at $367,000. Bank of New York Mellon Corp bought a new position in Unicycive Therapeutics during the 2nd quarter valued at about $248,000. Bank of America Corp DE boosted its holdings in Unicycive Therapeutics by 19,327.6% in the first quarter. Bank of America Corp DE now owns 29,530 shares of the company's stock worth $194,000 after purchasing an additional 29,378 shares during the last quarter. Finally, Renaissance Technologies LLC bought a new stake in shares of Unicycive Therapeutics in the first quarter worth $161,000. 40.42% of the stock is owned by institutional investors.

Unicycive Therapeutics News Roundup

Here are the key news stories impacting Unicycive Therapeutics this week:

• Positive Sentiment: Unicycive resubmitted its New Drug Application for oxylanthanum carbonate (OLC), an investigational phosphate binder for chronic kidney disease patients on dialysis. The company said the submission includes new manufacturing data addressing prior FDA concerns, expects acceptance within 30 days, and anticipates a new PDUFA decision date approximately six months after resubmission. This restores a potential regulatory catalyst, although FDA acceptance and approval are not guaranteed. Unicycive Therapeutics Announces Resubmission of New Drug Application for Oxylanthanum Carbonate
• Positive Sentiment: HC Wainwright maintained a “buy” rating while lowering its price target from $15 to $13. The revised target still implies substantial upside from the recent trading level, signaling that the analyst views the NDA resubmission and OLC opportunity as potentially valuable. HC Wainwright price target report
• Neutral Sentiment: Several law firms reminded investors of a November 2, 2026 deadline to seek lead-plaintiff status in a securities class action covering purchases made from December 29, 2025, through June 29, 2026. These announcements largely repeat the same lawsuit information rather than represent a new corporate event.
• Negative Sentiment: The litigation alleges that Unicycive failed to disclose that it had not inspected its third-party manufacturer’s facility for current good manufacturing practice compliance, an issue allegedly connected to a second FDA Complete Response Letter and a sharp prior stock-price decline. The allegations remain unproven, but the litigation creates legal costs, reputational risk, and additional uncertainty around OLC’s regulatory path. Levi & Korsinsky Unicycive lawsuit notice

About Unicycive Therapeutics

Unicycive Therapeutics, Inc is a clinical-stage biotechnology company focused on developing treatments for patients with kidney disease. The company's lead product candidate is oxylanthanum carbonate, an oral phosphate binder being developed to treat hyperphosphatemia, or elevated phosphate levels, in patients with chronic kidney disease, including those receiving dialysis.

Oxylanthanum carbonate is designed to bind dietary phosphate in the gastrointestinal tract, helping reduce the amount of phosphate absorbed into the bloodstream.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.